Announcements Trials
Browse Landscape

Phase

Phase 2 17Phase 3 5Phase 1 4Phase 1/2 3Phase 4 1

Status

Completed 2Unknown 1Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 3Tumor-Agnostic 1

Conditions

Breast Neoplasms 139Carcinoma, Non-Small-Cell Lung 109Prostatic Neoplasms 51Lung Neoplasms 31Neoplasm Metastasis 21Stomach Neoplasms 18Parkinson Disease 4, Autosomal Dominant Lewy Body 17Nasopharyngeal Carcinoma 16Neoplasms 15Squamous Cell Carcinoma of Head and Neck 14Esophageal Neoplasms 11Head and Neck Neoplasms 8Esophageal Squamous Cell Carcinoma 8Urinary Bladder Neoplasms 7HER2-positive Breast Cancer 7Ovarian Neoplasms 6Carcinoma 6Adenocarcinoma 6Inflammatory Breast Neoplasms 5Fallopian Tube Neoplasms 5Endometrial Neoplasms 5Carcinoma, Squamous Cell 5Adenocarcinoma of Lung 5Triple Negative Breast Neoplasms 4Recurrence 4Carcinoma, Transitional Cell 4Adenocarcinoma Of Esophagus 4Primary Breast Cancer 3Carcinoma, Ovarian Epithelial 3Adenocarcinoma, Bronchiolo-Alveolar 3

Interventions

Cisplatin 8Radiotherapy 5Paclitaxel 5Docetaxel 5Cetuximab 4Carboplatin 4pembrolizumab 3figitumumab 2cemiplimab 2advexin 2Radiation 2Methotrexate 2Fluorouracil 2Drug Therapy 2Bleomycin 2vandetanib 1talimogene laherparepvec 1sintilimab 1nedaplatin 1nanocis 1methyl 5-aminolevulinate 1ficlatuzumab 1dusquetide 1brigatinib 1avasopasem manganese 1alpha-2'-deoxythioguanosine 1Vinorelbine 1Tretinoin 1Tirapazamine 1Technetium-99 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Squamous Cell × Docetaxel × Clear all
NCT06908304 2026-01-12

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

Maia Biotechnology

Phase 3 Recruiting
300 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

NCT04171284 2024-02-09

SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer

Sinocelltech Ltd.

Phase 3 Terminated
188 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell

NCT02252042 2023-07-17

MK-3475-040

Merck Sharp & Dohme LLC

Phase 3 Completed
495 enrolled 32 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Squamous Cell

NCT02643407 2015-12-31

Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer

Guangdong Association of Clinical Trials

Phase 3 Unknown
488 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell

NCT00539630 2007-10-04

TAX + Cisplatin + 5 F/U vs Cisplatin + 5 F/U in SCCHN

Sanofi

Phase 3 Completed
86 enrolled
Tumor-Agnostic

Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡